



AUG. 1 1 2013

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 100-101

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

8

1

Complete if Known	
Application Number	09/891,138
Filing Date	June 25, 2001
First Named Inventor	Lin, Daniel Chi-Hong, et. al. 3 2003
Art Unit	1647 TECH CENTER 1600/2900
Examiner Name	Christopher J. Nichols
Attorney Docket Number	018781-006210US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ⁵ (If Known)			
CSJ	CB	PCT	WO 01/79449	A2	10/25/2001	Hyseq, Inc.
	CC	PCT	WO 01/90304	A2	11/29/2001	Human Genome Sciences, Inc.
	CD	PCT	WO 01/98351	A2	12/27/2001	Incyte Genomics, Inc.
↓	CE	PCT	WO 02/61087	A2	08/08/2002	Lifespan Biosciences, Inc.
CSJ	CF	PCT	WO 03/000893	A2	01/03/2003	Decode Genetics EHF.

Examiner Signature	G. diez	Date Considered	2/11/2004
-----------------------	---------	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 or 703-325-1000, 8:00 a.m. - 4:00 p.m., Monday-Friday.

RECEIVED

OCT 01 2002

PTO/SB/08B (10-01)

TECH CENTER 1600/2000

For official use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/891,138
Filing Date	June 25, 2001
First Named Inventor	Lin, Daniel Chi-Hong, et. al.
Art Unit	1646 1647
Examiner Name	Not yet assigned NICHOLS
Attorney Docket Number	018781-006210US

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴				
CGN	BA	EP	1 096 009	A1	05/02/2001	Pfizer Limited et al.	<input type="checkbox"/>
	BB	WO	00/22131	A2	04/20/2000	Dominic P. Behan et al.	<input type="checkbox"/>
	BC	WO	00/31258	A2	08/02/2000	Ruoping Chen et al.	<input type="checkbox"/>
	BD	WO	01/25432	A2	04/12/2001	Schering Corporation	<input type="checkbox"/>
	BE	WO	01/33221	A1	05/10/2001	SmithKline Beecham Corporation et al	<input type="checkbox"/>
	BF	WO	01/46414	A1	06/28/2001	Banyu Pharmaceutical CO., LTD.	<input type="checkbox"/>
	BG	WO	01/85793	A2	11/15/2001	Pharmacia & Upjohn Company	<input type="checkbox"/>

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
CGN	BH	STADEL J. et al., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" Trends in Pharmacological Sciences, Elsevier Trends Journal, Cambridge, GB, vol. 18, no. 11, pp. 430-437, (November 1, 1997)			<input type="checkbox"/>
					<input type="checkbox"/>
					<input type="checkbox"/>
					<input type="checkbox"/>
					<input type="checkbox"/>
					<input type="checkbox"/>

Examiner
Signature*gillis*Date
Considered

4/8/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1388300 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OCT 09 2001

JCBG

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/891,138
Filing Date	June 25, 2001
First Named Inventor	Lin, Daniel Chi-Hong
Group Art Unit	1647
Examiner Name	Nichols
Attorney Docket Number	018781-00624MUSC

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
GD	AA	US 5,871,963	A	Conley, et al.	02-16-1999	
GD	AB	US 5,955,309	A	Ellis, et al.	09-21-1999	
GD	AC	US 6,063,582	A	Conley, et al.	05-16-2000	
GD	AD	US 6,204,017	B1	Behan, et al.	03-20-2001	
GD	AE	US 6,222,029	B1	Edwards, et al.	04-24-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
GD	AF	EPO	WO 96/05302	A1	Takeda Chemical Industries, LTD.	02-22-1996		
	AG	EPO	WO 97/24929	A1	Human Genome Sciences, Inc.	07-17-1997		
	AH	EPO	WO 99/06552	A2	Genset	02-11-1999		
	AI	EPO	WO 00/11166	A1	Millennium Pharmaceuticals, Inc.	03-02-2000		
	AJ	EPO	WO 00/22131	A2	Behan, et al.	04-20-2000		
	AK	EPO	WO 00/28032	A2	Incite Pharmaceuticals, Inc.	05-18-2000		
	AL	EPO	WO 00/61628	A1	Human Genome Sciences, Inc.	10-19-2000		
	AM	EPO	WO 01/31014	A2	Pharmacia & Upjohn Company	05-03-2001		
	AN	EPO	WO 00/31258	A2	Arena Pharmaceuticals, Inc.	06-02-2000		
✓	AO	EPO	WO 01/36473	A2	Pharmacia & Upjohn Company	05-25-2001		
GD	AP	EPO	EP 1090925	A1	Pfizer Limited	04-11-2001		

Examiner Signature

G. Nichols

Date Considered

4/8/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1277930 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

Attorney Docket Number

Complete If Known

Application Number

09/891,138

Filing Date

June 25, 2001

First Named Inventor

Lin, Daniel Chi-Hong

Group Art Unit

1640 1647

Examiner Name

NIC HOLS

RECEIVED
TECH CENTER 1600
OCT 12 2001
1600/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
CGD	AQ	EPO	EP 1096009	A1	Pfizer Limited	05-02-2001	_____	_____
	AR	EPO	EP 0892051	A2	Smithkline Beecham Corporation	01-20-1999	_____	_____
	AS	EPO	EP 0892051	A3	Smithkline Beecham Corporation	01-20-1999	_____	_____
↓	AT	JPO	08-245697		Takeda Chemical Industries, LTD.	09-24-1996	_____	_____
GGD	AU	JPO	11032770	A	Asahi Kasei Kogyo KK	07-24-1997	_____	_____

Examiner Signature

Date Considered

4/8/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

SF 1277930 v1